JPL Wealth Management’s Vaxcyte PCVX Stock Holding History

JPL Wealth Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$291	Hold	5	–	–	﹤0.01%	1474
2026 Q1	$291	Buy	+5	New	+$271	﹤0.01%	1370
2025 Q4	–	Sell	-5	Closed	-$181	–	828
2025 Q3	$181	Buy	+5	New	+$166	﹤0.01%	1151

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

JPL Wealth Management's PCVX Position: Q2 2026 in Review

JPL Wealth Management held its Vaxcyte (PCVX) position steady in Q2 2026 at 5 shares worth $291. The position accounts for ﹤0.01% of the portfolio, ranked #1474.

JPL Wealth Management first reported a position in PCVX in Q3 2025 and has held it in 3 quarters since. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

JPL Wealth Management held 5 shares of Vaxcyte worth $291 as of Q2 2026.
JPL Wealth Management left its Vaxcyte share count unchanged in Q2 2026.
Vaxcyte made up ﹤0.01% of JPL Wealth Management's portfolio in Q2 2026, its #1474 holding.
JPL Wealth Management first reported a position in Vaxcyte in Q3 2025 and has held it in 3 quarters since.
332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on JPL Wealth Management's 13F filing for Q2 2026, filed 14 Aug 2026.